Showing results (2111-2120 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 1, 1992
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I studyE A Poplin, T Corbett, L Flaherty, et al.
Investigational New Drugs|August 1, 1992
Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticlesJ Kattan, J P Droz, P Couvreur, et al.
Investigational New Drugs|August 1, 1992
A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group studyB R Murphy, S M Rynard, L H Einhorn, et al.
Investigational New Drugs|January 30, 2010
LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatinJian-Jun Gao, Zu-Hua Gao, Cui-Rong Zhao, et al.
Investigational New Drugs|February 2, 2010
AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivoMylin A Torres, Uma Raju, David Molkentine, et al.
Investigational New Drugs|January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsHoward A Burris, Suzanne F Jones, Daphne D Williams, et al.
Investigational New Drugs|May 1, 1993
Is there a role for vindesine in the treatment of non-small cell lung cancer?J B Sørensen, H H Hansen
Investigational New Drugs|May 1, 1993
Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology GroupJ H Saiki, W J Stuckey, J W Athens, et al.
Investigational New Drugs|May 1, 1993
Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group studyM E Marshall, M K Wolf, E D Crawford, et al.
Investigational New Drugs|May 1, 1993
Phase II trial of amonafide in advanced pancreas cancer. A Southwest Oncology Group studyC G Leichman, C Tangen, J S Macdonald, et al.
Pageof 372